| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Esophageal Neoplasms | 174 | 2023 | 3168 | 10.060 |
Why?
|
| Lung Neoplasms | 218 | 2023 | 11538 | 7.690 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 146 | 2023 | 5319 | 7.180 |
Why?
|
| Esophagectomy | 82 | 2022 | 911 | 5.380 |
Why?
|
| Adenocarcinoma | 143 | 2023 | 7789 | 5.180 |
Why?
|
| Neoadjuvant Therapy | 72 | 2023 | 4975 | 3.140 |
Why?
|
| Pneumonectomy | 44 | 2023 | 831 | 3.130 |
Why?
|
| eIF-2 Kinase | 17 | 2019 | 164 | 3.090 |
Why?
|
| Esophagogastric Junction | 34 | 2023 | 543 | 3.020 |
Why?
|
| Carcinoma, Squamous Cell | 70 | 2021 | 5437 | 2.690 |
Why?
|
| Chemoradiotherapy | 29 | 2021 | 1946 | 2.220 |
Why?
|
| Neoplasm Staging | 141 | 2023 | 13658 | 2.210 |
Why?
|
| Neoplasm Recurrence, Local | 61 | 2023 | 10035 | 1.570 |
Why?
|
| Aged | 255 | 2022 | 70117 | 1.520 |
Why?
|
| Humans | 471 | 2023 | 261506 | 1.500 |
Why?
|
| Adenoviridae | 31 | 2016 | 1459 | 1.490 |
Why?
|
| Genetic Therapy | 26 | 2007 | 1616 | 1.480 |
Why?
|
| Middle Aged | 270 | 2022 | 86204 | 1.460 |
Why?
|
| Positron-Emission Tomography | 24 | 2021 | 2173 | 1.430 |
Why?
|
| Combined Modality Therapy | 87 | 2023 | 8865 | 1.400 |
Why?
|
| Retrospective Studies | 166 | 2023 | 37905 | 1.370 |
Why?
|
| Male | 305 | 2022 | 123000 | 1.340 |
Why?
|
| Survival Rate | 82 | 2023 | 12221 | 1.340 |
Why?
|
| Interleukins | 9 | 2008 | 325 | 1.330 |
Why?
|
| Female | 317 | 2023 | 141928 | 1.290 |
Why?
|
| Prognosis | 109 | 2023 | 21713 | 1.280 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 57 | 2023 | 15862 | 1.260 |
Why?
|
| Fluorodeoxyglucose F18 | 15 | 2021 | 1226 | 1.180 |
Why?
|
| Pleural Neoplasms | 11 | 2021 | 470 | 1.160 |
Why?
|
| Endosonography | 11 | 2015 | 536 | 1.130 |
Why?
|
| Genes, p53 | 19 | 2006 | 1090 | 1.070 |
Why?
|
| Induction Chemotherapy | 8 | 2018 | 669 | 1.040 |
Why?
|
| Aged, 80 and over | 116 | 2021 | 29902 | 1.030 |
Why?
|
| Salvage Therapy | 16 | 2021 | 2054 | 1.030 |
Why?
|
| Adult | 178 | 2023 | 77950 | 0.980 |
Why?
|
| Radiosurgery | 11 | 2019 | 1330 | 0.980 |
Why?
|
| Chemoradiotherapy, Adjuvant | 14 | 2021 | 565 | 0.940 |
Why?
|
| Apoptosis | 37 | 2020 | 7591 | 0.930 |
Why?
|
| Thoracic Surgery, Video-Assisted | 8 | 2022 | 209 | 0.920 |
Why?
|
| Treatment Outcome | 112 | 2023 | 32848 | 0.910 |
Why?
|
| Metastasectomy | 6 | 2023 | 200 | 0.900 |
Why?
|
| Survival Analysis | 57 | 2020 | 9180 | 0.890 |
Why?
|
| Lymph Nodes | 15 | 2021 | 2967 | 0.890 |
Why?
|
| Postoperative Complications | 37 | 2022 | 5542 | 0.880 |
Why?
|
| Neoplasm, Residual | 13 | 2018 | 1656 | 0.880 |
Why?
|
| Follow-Up Studies | 59 | 2021 | 14889 | 0.860 |
Why?
|
| Esophagoscopy | 7 | 2021 | 291 | 0.850 |
Why?
|
| Disease-Free Survival | 55 | 2021 | 10001 | 0.850 |
Why?
|
| Thoracic Surgical Procedures | 9 | 2022 | 261 | 0.830 |
Why?
|
| Radiopharmaceuticals | 10 | 2021 | 1301 | 0.820 |
Why?
|
| Lymphatic Metastasis | 35 | 2021 | 4844 | 0.820 |
Why?
|
| Gene Expression Regulation, Neoplastic | 33 | 2021 | 8873 | 0.810 |
Why?
|
| Biomarkers, Tumor | 37 | 2023 | 10331 | 0.800 |
Why?
|
| Mesothelioma | 8 | 2018 | 544 | 0.760 |
Why?
|
| Cisplatin | 26 | 2021 | 2432 | 0.760 |
Why?
|
| Preoperative Care | 20 | 2019 | 1529 | 0.740 |
Why?
|
| Gene Transfer Techniques | 18 | 2006 | 716 | 0.740 |
Why?
|
| Genetic Vectors | 24 | 2016 | 1694 | 0.740 |
Why?
|
| Fluorouracil | 26 | 2019 | 1944 | 0.720 |
Why?
|
| Chemotherapy, Adjuvant | 35 | 2021 | 3890 | 0.690 |
Why?
|
| Tomography, X-Ray Computed | 23 | 2018 | 7551 | 0.680 |
Why?
|
| Unfolded Protein Response | 1 | 2019 | 115 | 0.680 |
Why?
|
| Antineoplastic Agents | 31 | 2019 | 14289 | 0.670 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2019 | 129 | 0.670 |
Why?
|
| B7-H1 Antigen | 10 | 2023 | 1022 | 0.660 |
Why?
|
| Digestive System Surgical Procedures | 4 | 2013 | 275 | 0.650 |
Why?
|
| Propensity Score | 10 | 2021 | 750 | 0.640 |
Why?
|
| Esophagus | 8 | 2012 | 553 | 0.640 |
Why?
|
| Mutation | 34 | 2023 | 15179 | 0.630 |
Why?
|
| Small Cell Lung Carcinoma | 5 | 2023 | 406 | 0.630 |
Why?
|
| Rad51 Recombinase | 1 | 2018 | 126 | 0.620 |
Why?
|
| Organ Sparing Treatments | 2 | 2016 | 277 | 0.620 |
Why?
|
| Thymoma | 5 | 2013 | 246 | 0.610 |
Why?
|
| Kaplan-Meier Estimate | 35 | 2019 | 6207 | 0.610 |
Why?
|
| Proteolysis | 1 | 2019 | 370 | 0.610 |
Why?
|
| Patient Selection | 13 | 2021 | 2055 | 0.610 |
Why?
|
| Circulating Tumor DNA | 4 | 2023 | 235 | 0.600 |
Why?
|
| Thymus Neoplasms | 5 | 2020 | 400 | 0.600 |
Why?
|
| Proportional Hazards Models | 35 | 2021 | 4988 | 0.590 |
Why?
|
| Radiation Pneumonitis | 5 | 2018 | 301 | 0.590 |
Why?
|
| Lysosomes | 1 | 2019 | 347 | 0.590 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 8 | 2022 | 992 | 0.560 |
Why?
|
| Radiotherapy, Adjuvant | 25 | 2018 | 2231 | 0.560 |
Why?
|
| Cohort Studies | 30 | 2022 | 9244 | 0.550 |
Why?
|
| Neoplasms, Multiple Primary | 3 | 2019 | 551 | 0.540 |
Why?
|
| Multivariate Analysis | 30 | 2019 | 4298 | 0.540 |
Why?
|
| Genes, Tumor Suppressor | 12 | 2019 | 1064 | 0.520 |
Why?
|
| Endoplasmic Reticulum | 5 | 2009 | 308 | 0.520 |
Why?
|
| Tumor Cells, Cultured | 27 | 2020 | 5395 | 0.510 |
Why?
|
| Neoplasm Invasiveness | 24 | 2019 | 3981 | 0.510 |
Why?
|
| Stomach Neoplasms | 12 | 2023 | 2278 | 0.490 |
Why?
|
| Consolidation Chemotherapy | 3 | 2019 | 155 | 0.490 |
Why?
|
| Anastomosis, Surgical | 8 | 2014 | 371 | 0.490 |
Why?
|
| Cell Survival | 11 | 2019 | 3045 | 0.470 |
Why?
|
| Lung | 20 | 2023 | 3151 | 0.470 |
Why?
|
| Barrett Esophagus | 8 | 2021 | 569 | 0.470 |
Why?
|
| Pharmacogenetics | 1 | 2015 | 260 | 0.470 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2013 | 60 | 0.450 |
Why?
|
| Colorectal Neoplasms | 8 | 2023 | 3578 | 0.450 |
Why?
|
| RNA, Double-Stranded | 5 | 2008 | 79 | 0.450 |
Why?
|
| Radiotherapy, Intensity-Modulated | 9 | 2020 | 2104 | 0.440 |
Why?
|
| Cell Line, Tumor | 29 | 2021 | 14551 | 0.440 |
Why?
|
| Genetic Heterogeneity | 5 | 2020 | 318 | 0.440 |
Why?
|
| Time Factors | 32 | 2021 | 12926 | 0.440 |
Why?
|
| Proton Therapy | 7 | 2020 | 1577 | 0.430 |
Why?
|
| Taxoids | 10 | 2019 | 967 | 0.430 |
Why?
|
| Jejunum | 3 | 2012 | 216 | 0.430 |
Why?
|
| Lung Diseases | 6 | 2021 | 717 | 0.420 |
Why?
|
| Benzoquinones | 3 | 2007 | 108 | 0.420 |
Why?
|
| Neoplasm Metastasis | 16 | 2021 | 5112 | 0.420 |
Why?
|
| Pain Management | 4 | 2021 | 668 | 0.420 |
Why?
|
| Pain, Postoperative | 3 | 2021 | 610 | 0.410 |
Why?
|
| Tumor Necrosis Factor-alpha | 6 | 2015 | 1538 | 0.410 |
Why?
|
| Carboplatin | 7 | 2017 | 823 | 0.400 |
Why?
|
| Kruppel-Like Transcription Factors | 2 | 2010 | 270 | 0.390 |
Why?
|
| Osteonectin | 2 | 2010 | 53 | 0.390 |
Why?
|
| Texas | 26 | 2020 | 6311 | 0.390 |
Why?
|
| Antibodies, Monoclonal | 5 | 2022 | 4367 | 0.390 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2017 | 690 | 0.390 |
Why?
|
| Transfection | 8 | 2016 | 2944 | 0.390 |
Why?
|
| ErbB Receptors | 11 | 2023 | 2295 | 0.390 |
Why?
|
| Neoplasms | 10 | 2023 | 15193 | 0.390 |
Why?
|
| Drug Resistance, Neoplasm | 13 | 2020 | 5178 | 0.380 |
Why?
|
| Tomography, Emission-Computed | 2 | 2009 | 310 | 0.370 |
Why?
|
| Precision Medicine | 4 | 2020 | 1154 | 0.370 |
Why?
|
| Prospective Studies | 28 | 2022 | 12873 | 0.370 |
Why?
|
| Databases, Factual | 16 | 2020 | 2218 | 0.370 |
Why?
|
| Risk Factors | 34 | 2023 | 17523 | 0.370 |
Why?
|
| Carcinoma, Neuroendocrine | 5 | 2021 | 716 | 0.370 |
Why?
|
| Thoracic Neoplasms | 5 | 2018 | 337 | 0.370 |
Why?
|
| Tumor Microenvironment | 9 | 2022 | 2864 | 0.360 |
Why?
|
| Lactams, Macrocyclic | 2 | 2007 | 90 | 0.360 |
Why?
|
| Camptothecin | 6 | 2014 | 517 | 0.360 |
Why?
|
| Thoracotomy | 7 | 2022 | 220 | 0.350 |
Why?
|
| Paclitaxel | 13 | 2016 | 1996 | 0.350 |
Why?
|
| Thoracic Wall | 3 | 2018 | 183 | 0.350 |
Why?
|
| Membrane Proteins | 7 | 2014 | 2819 | 0.340 |
Why?
|
| Cytochrome c Group | 3 | 2003 | 71 | 0.340 |
Why?
|
| Predictive Value of Tests | 19 | 2020 | 4892 | 0.330 |
Why?
|
| Tumor Burden | 12 | 2023 | 1987 | 0.330 |
Why?
|
| Proto-Oncogene Proteins c-akt | 5 | 2016 | 2054 | 0.330 |
Why?
|
| Calcium | 2 | 2013 | 1537 | 0.320 |
Why?
|
| Patient Discharge | 4 | 2021 | 661 | 0.320 |
Why?
|
| Immunohistochemistry | 18 | 2020 | 7548 | 0.310 |
Why?
|
| Radiotherapy Dosage | 15 | 2019 | 3842 | 0.310 |
Why?
|
| Pancreatitis | 3 | 1994 | 267 | 0.310 |
Why?
|
| Surgical Wound Infection | 3 | 2017 | 450 | 0.310 |
Why?
|
| Blotting, Western | 14 | 2017 | 3536 | 0.310 |
Why?
|
| Proto-Oncogene Proteins | 8 | 2015 | 2488 | 0.310 |
Why?
|
| Mitochondria | 4 | 2003 | 1282 | 0.300 |
Why?
|
| Ultrasonography, Interventional | 2 | 2012 | 429 | 0.300 |
Why?
|
| Radiation Tolerance | 6 | 2020 | 629 | 0.300 |
Why?
|
| Transduction, Genetic | 4 | 2012 | 475 | 0.300 |
Why?
|
| Radiotherapy, Conformal | 6 | 2015 | 902 | 0.300 |
Why?
|
| Young Adult | 28 | 2021 | 21445 | 0.300 |
Why?
|
| Xenograft Model Antitumor Assays | 7 | 2020 | 3821 | 0.290 |
Why?
|
| Patient Readmission | 3 | 2021 | 548 | 0.290 |
Why?
|
| NF-kappa B | 4 | 2007 | 1549 | 0.290 |
Why?
|
| Gene Expression Profiling | 9 | 2021 | 5159 | 0.290 |
Why?
|
| Incidence | 15 | 2021 | 5673 | 0.280 |
Why?
|
| Ulcer | 1 | 2006 | 78 | 0.270 |
Why?
|
| Organoplatinum Compounds | 7 | 2019 | 702 | 0.270 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2019 | 2359 | 0.270 |
Why?
|
| Mice | 31 | 2021 | 34495 | 0.270 |
Why?
|
| Risk Assessment | 18 | 2020 | 6869 | 0.270 |
Why?
|
| Esophageal Diseases | 1 | 2006 | 69 | 0.270 |
Why?
|
| Biomarkers | 4 | 2022 | 5047 | 0.270 |
Why?
|
| Lymph Node Excision | 6 | 2021 | 1959 | 0.270 |
Why?
|
| Postoperative Care | 6 | 2021 | 739 | 0.270 |
Why?
|
| Pleura | 2 | 2021 | 127 | 0.260 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2018 | 1062 | 0.260 |
Why?
|
| Caspases | 5 | 2004 | 661 | 0.260 |
Why?
|
| Flow Cytometry | 11 | 2017 | 3033 | 0.260 |
Why?
|
| Ipilimumab | 4 | 2023 | 710 | 0.260 |
Why?
|
| Robotic Surgical Procedures | 3 | 2021 | 481 | 0.260 |
Why?
|
| Sarcoma | 8 | 2018 | 1725 | 0.260 |
Why?
|
| Length of Stay | 12 | 2018 | 1900 | 0.250 |
Why?
|
| Sensitivity and Specificity | 12 | 2013 | 4971 | 0.250 |
Why?
|
| Proto-Oncogene Proteins c-met | 2 | 2018 | 419 | 0.250 |
Why?
|
| Natural Language Processing | 3 | 2018 | 119 | 0.250 |
Why?
|
| Cell Proliferation | 15 | 2020 | 7226 | 0.250 |
Why?
|
| Radiotherapy | 11 | 2020 | 1824 | 0.250 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 9 | 2008 | 1493 | 0.250 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2007 | 703 | 0.250 |
Why?
|
| Nomograms | 4 | 2020 | 313 | 0.250 |
Why?
|
| NF-E2-Related Factor 2 | 2 | 2020 | 249 | 0.240 |
Why?
|
| Analysis of Variance | 14 | 2018 | 2307 | 0.240 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2015 | 1756 | 0.240 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2018 | 4757 | 0.240 |
Why?
|
| Spinal Neoplasms | 5 | 2009 | 631 | 0.240 |
Why?
|
| Animals | 37 | 2021 | 59536 | 0.240 |
Why?
|
| Bridged-Ring Compounds | 4 | 2019 | 183 | 0.240 |
Why?
|
| Biopsy | 9 | 2020 | 3443 | 0.240 |
Why?
|
| Remission Induction | 10 | 2017 | 3569 | 0.240 |
Why?
|
| Immunotherapy | 8 | 2023 | 3341 | 0.240 |
Why?
|
| Analgesics, Opioid | 4 | 2021 | 1371 | 0.240 |
Why?
|
| Phosphorylation | 11 | 2013 | 4804 | 0.240 |
Why?
|
| Cell Movement | 2 | 2018 | 2466 | 0.240 |
Why?
|
| Carcinoma, Signet Ring Cell | 2 | 2020 | 170 | 0.230 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 2 | 2013 | 89 | 0.230 |
Why?
|
| Immune System Diseases | 1 | 2023 | 65 | 0.230 |
Why?
|
| Carcinoma, Large Cell | 2 | 2021 | 94 | 0.230 |
Why?
|
| Thoracic Vertebrae | 3 | 2009 | 186 | 0.230 |
Why?
|
| Logistic Models | 13 | 2019 | 3441 | 0.220 |
Why?
|
| Sarcoma, Experimental | 1 | 2003 | 68 | 0.220 |
Why?
|
| Tumor Suppressor Protein p53 | 8 | 2010 | 3552 | 0.220 |
Why?
|
| Depsipeptides | 1 | 2003 | 78 | 0.220 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2003 | 48 | 0.220 |
Why?
|
| Treatment Failure | 8 | 2017 | 1391 | 0.220 |
Why?
|
| Mice, SCID | 4 | 2019 | 1869 | 0.220 |
Why?
|
| Anastomotic Leak | 2 | 2013 | 71 | 0.210 |
Why?
|
| Peptides, Cyclic | 1 | 2003 | 139 | 0.210 |
Why?
|
| Hospitals | 2 | 2023 | 485 | 0.210 |
Why?
|
| Thyroid Diseases | 1 | 2022 | 85 | 0.210 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 2 | 2020 | 104 | 0.210 |
Why?
|
| Enzyme Activation | 8 | 2013 | 1764 | 0.210 |
Why?
|
| Melanoma | 7 | 2023 | 5317 | 0.210 |
Why?
|
| Folic Acid Antagonists | 1 | 2022 | 45 | 0.210 |
Why?
|
| Flavonoids | 1 | 2003 | 188 | 0.210 |
Why?
|
| Pleural Effusion, Malignant | 2 | 2020 | 156 | 0.210 |
Why?
|
| Registries | 6 | 2018 | 2170 | 0.200 |
Why?
|
| Hospital Mortality | 4 | 2018 | 1274 | 0.200 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2003 | 311 | 0.200 |
Why?
|
| Carcinoma | 8 | 2012 | 2578 | 0.200 |
Why?
|
| Cyclins | 1 | 2003 | 456 | 0.200 |
Why?
|
| Pulmonary Surgical Procedures | 1 | 2021 | 24 | 0.200 |
Why?
|
| CD8-Positive T-Lymphocytes | 7 | 2023 | 1586 | 0.200 |
Why?
|
| Growth Substances | 1 | 2002 | 300 | 0.200 |
Why?
|
| Indoles | 3 | 2020 | 1009 | 0.200 |
Why?
|
| Chest Tubes | 1 | 2021 | 101 | 0.200 |
Why?
|
| Signal Transduction | 7 | 2018 | 11965 | 0.200 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2022 | 709 | 0.200 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2020 | 607 | 0.200 |
Why?
|
| Up-Regulation | 6 | 2010 | 2450 | 0.190 |
Why?
|
| Genomics | 6 | 2021 | 2738 | 0.190 |
Why?
|
| Cancer Care Facilities | 7 | 2019 | 884 | 0.190 |
Why?
|
| Multimodal Imaging | 5 | 2021 | 550 | 0.190 |
Why?
|
| Glutaminase | 1 | 2020 | 47 | 0.190 |
Why?
|
| Hospital Bed Capacity | 1 | 2000 | 27 | 0.190 |
Why?
|
| Fibroblasts | 1 | 2007 | 1682 | 0.190 |
Why?
|
| Perioperative Care | 3 | 2019 | 451 | 0.190 |
Why?
|
| SEER Program | 5 | 2015 | 1000 | 0.190 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 8 | 2018 | 2370 | 0.190 |
Why?
|
| Surgical Flaps | 4 | 2012 | 927 | 0.190 |
Why?
|
| Interleukin-2 | 6 | 2009 | 842 | 0.190 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 2000 | 34 | 0.190 |
Why?
|
| Bupivacaine | 1 | 2020 | 68 | 0.180 |
Why?
|
| Heterografts | 3 | 2019 | 733 | 0.180 |
Why?
|
| Transcriptome | 4 | 2021 | 1859 | 0.180 |
Why?
|
| Thoracentesis | 1 | 2020 | 59 | 0.180 |
Why?
|
| Esophagoplasty | 2 | 2012 | 27 | 0.180 |
Why?
|
| Hospital Costs | 2 | 2013 | 228 | 0.180 |
Why?
|
| Surgical Equipment | 1 | 2019 | 17 | 0.180 |
Why?
|
| Genome, Human | 3 | 2020 | 1869 | 0.180 |
Why?
|
| Mucous Membrane | 4 | 2015 | 271 | 0.180 |
Why?
|
| Bronchial Diseases | 1 | 2020 | 45 | 0.180 |
Why?
|
| Organs at Risk | 3 | 2012 | 514 | 0.180 |
Why?
|
| Appointments and Schedules | 1 | 2020 | 98 | 0.180 |
Why?
|
| E2F1 Transcription Factor | 5 | 2010 | 206 | 0.180 |
Why?
|
| Gene Expression | 9 | 2017 | 3570 | 0.180 |
Why?
|
| Antigens, Neoplasm | 3 | 2017 | 1506 | 0.180 |
Why?
|
| Auranofin | 2 | 2018 | 38 | 0.180 |
Why?
|
| Protein Folding | 2 | 2019 | 281 | 0.180 |
Why?
|
| Pregnancy Complications | 2 | 1994 | 526 | 0.180 |
Why?
|
| Retreatment | 1 | 2020 | 452 | 0.180 |
Why?
|
| Eukaryotic Initiation Factor-2 | 2 | 2011 | 92 | 0.180 |
Why?
|
| Gastrectomy | 5 | 2023 | 451 | 0.170 |
Why?
|
| Piperidines | 2 | 2014 | 1035 | 0.170 |
Why?
|
| Cell Nucleus | 4 | 2017 | 1620 | 0.170 |
Why?
|
| United States | 17 | 2021 | 15433 | 0.170 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 5 | 2006 | 72 | 0.170 |
Why?
|
| Mice, Nude | 7 | 2021 | 4307 | 0.170 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2019 | 110 | 0.170 |
Why?
|
| Genes, erbB-1 | 2 | 2018 | 101 | 0.170 |
Why?
|
| Thioredoxin-Disulfide Reductase | 1 | 2018 | 8 | 0.170 |
Why?
|
| Glutathione Reductase | 1 | 2018 | 17 | 0.170 |
Why?
|
| Postoperative Hemorrhage | 1 | 2020 | 162 | 0.170 |
Why?
|
| Disease Progression | 14 | 2021 | 6682 | 0.170 |
Why?
|
| Glutamate-Cysteine Ligase | 1 | 2018 | 26 | 0.170 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 5 | 2023 | 1331 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 4 | 2010 | 528 | 0.170 |
Why?
|
| Erlotinib Hydrochloride | 2 | 2017 | 388 | 0.170 |
Why?
|
| Dasatinib | 2 | 2020 | 862 | 0.170 |
Why?
|
| Synthetic Lethal Mutations | 1 | 2018 | 25 | 0.170 |
Why?
|
| RNA, Messenger | 9 | 2018 | 6150 | 0.170 |
Why?
|
| Immunomodulation | 2 | 2017 | 242 | 0.170 |
Why?
|
| Immunity | 1 | 2021 | 342 | 0.160 |
Why?
|
| Thioredoxins | 1 | 2018 | 50 | 0.160 |
Why?
|
| Pancoast Syndrome | 2 | 2013 | 9 | 0.160 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2019 | 1249 | 0.160 |
Why?
|
| Endoscopic Mucosal Resection | 1 | 2019 | 94 | 0.160 |
Why?
|
| Acrylamides | 1 | 2018 | 53 | 0.160 |
Why?
|
| Diffusion of Innovation | 1 | 2019 | 160 | 0.160 |
Why?
|
| Vaccinia virus | 2 | 2008 | 79 | 0.160 |
Why?
|
| Evolution, Molecular | 2 | 2020 | 834 | 0.160 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2011 | 3639 | 0.160 |
Why?
|
| Precancerous Conditions | 2 | 2019 | 1058 | 0.160 |
Why?
|
| Enzyme Inhibitors | 4 | 2017 | 1879 | 0.160 |
Why?
|
| Tissue Array Analysis | 5 | 2013 | 760 | 0.160 |
Why?
|
| Spinal Fusion | 1 | 1999 | 149 | 0.160 |
Why?
|
| Cholelithiasis | 2 | 1994 | 43 | 0.160 |
Why?
|
| Drug Administration Schedule | 7 | 2019 | 3472 | 0.160 |
Why?
|
| T-Lymphocytes | 3 | 2020 | 3869 | 0.160 |
Why?
|
| Transcription Factors | 6 | 2021 | 5270 | 0.160 |
Why?
|
| Surgical Oncology | 1 | 2020 | 190 | 0.160 |
Why?
|
| Patient Satisfaction | 2 | 2016 | 915 | 0.160 |
Why?
|
| Preoperative Period | 3 | 2013 | 344 | 0.160 |
Why?
|
| Reoperation | 6 | 2019 | 1382 | 0.160 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2016 | 1546 | 0.150 |
Why?
|
| Radiography, Thoracic | 3 | 2020 | 462 | 0.150 |
Why?
|
| Adolescent | 19 | 2023 | 31252 | 0.150 |
Why?
|
| Oncogenes | 4 | 2022 | 673 | 0.150 |
Why?
|
| Heparin | 1 | 2019 | 360 | 0.150 |
Why?
|
| Serine Proteases | 1 | 2017 | 20 | 0.150 |
Why?
|
| Statistics, Nonparametric | 7 | 2018 | 980 | 0.150 |
Why?
|
| Thoracic Surgery | 1 | 2021 | 295 | 0.150 |
Why?
|
| Aniline Compounds | 1 | 2018 | 177 | 0.150 |
Why?
|
| Inpatients | 1 | 2022 | 678 | 0.150 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2017 | 111 | 0.150 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2019 | 224 | 0.150 |
Why?
|
| Epithelium | 1 | 2019 | 720 | 0.150 |
Why?
|
| Ticlopidine | 1 | 2017 | 95 | 0.150 |
Why?
|
| Stomach | 2 | 2012 | 387 | 0.150 |
Why?
|
| Margins of Excision | 1 | 2018 | 285 | 0.150 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2019 | 2291 | 0.140 |
Why?
|
| Thoracoplasty | 1 | 2016 | 20 | 0.140 |
Why?
|
| Medical Oncology | 2 | 2018 | 1423 | 0.140 |
Why?
|
| Exosomes | 1 | 2019 | 253 | 0.140 |
Why?
|
| Polytetrafluoroethylene | 1 | 2017 | 113 | 0.140 |
Why?
|
| Doxorubicin | 2 | 2004 | 3005 | 0.140 |
Why?
|
| Glutathione | 1 | 2018 | 368 | 0.140 |
Why?
|
| RNA, Neoplasm | 2 | 2017 | 771 | 0.140 |
Why?
|
| Patient Safety | 2 | 2019 | 649 | 0.140 |
Why?
|
| Hospital Charges | 2 | 2015 | 75 | 0.140 |
Why?
|
| Allelic Imbalance | 1 | 2016 | 41 | 0.140 |
Why?
|
| DNA Repair Enzymes | 1 | 2017 | 237 | 0.140 |
Why?
|
| Polymorphism, Genetic | 3 | 2007 | 1450 | 0.140 |
Why?
|
| Peritoneal Neoplasms | 1 | 2023 | 821 | 0.140 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2017 | 113 | 0.140 |
Why?
|
| HLA Antigens | 1 | 2019 | 546 | 0.140 |
Why?
|
| Databases, Genetic | 1 | 2019 | 745 | 0.140 |
Why?
|
| Cyclin D1 | 3 | 2009 | 576 | 0.140 |
Why?
|
| Antigen Presentation | 1 | 2017 | 272 | 0.140 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2017 | 134 | 0.140 |
Why?
|
| Neoplasm Transplantation | 3 | 2017 | 1519 | 0.140 |
Why?
|
| Patient Care Team | 3 | 2004 | 795 | 0.140 |
Why?
|
| Dose-Response Relationship, Radiation | 5 | 2009 | 726 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2016 | 2594 | 0.140 |
Why?
|
| Platinum Compounds | 3 | 2013 | 131 | 0.140 |
Why?
|
| Odds Ratio | 6 | 2021 | 2316 | 0.140 |
Why?
|
| Diaphragm | 1 | 2017 | 181 | 0.130 |
Why?
|
| MAP Kinase Kinase Kinase 5 | 1 | 2015 | 19 | 0.130 |
Why?
|
| Recurrence | 6 | 2023 | 4758 | 0.130 |
Why?
|
| Anilides | 1 | 2017 | 268 | 0.130 |
Why?
|
| Acellular Dermis | 1 | 2017 | 103 | 0.130 |
Why?
|
| Smoking Cessation | 1 | 2021 | 712 | 0.130 |
Why?
|
| TNF Receptor-Associated Factor 2 | 1 | 2015 | 39 | 0.130 |
Why?
|
| Neutrophils | 1 | 2020 | 835 | 0.130 |
Why?
|
| Chi-Square Distribution | 6 | 2017 | 1323 | 0.130 |
Why?
|
| Anterior Temporal Lobectomy | 1 | 2015 | 32 | 0.130 |
Why?
|
| Serous Membrane | 1 | 2015 | 9 | 0.130 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2018 | 252 | 0.130 |
Why?
|
| Platinum | 2 | 2013 | 138 | 0.130 |
Why?
|
| Radiation Injuries | 5 | 2012 | 1411 | 0.130 |
Why?
|
| Arylsulfotransferase | 1 | 2015 | 18 | 0.130 |
Why?
|
| Colic | 1 | 1994 | 14 | 0.130 |
Why?
|
| Hemorrhage | 1 | 2019 | 712 | 0.130 |
Why?
|
| Treatment Refusal | 2 | 2013 | 128 | 0.130 |
Why?
|
| DNA-Binding Proteins | 7 | 2017 | 4821 | 0.130 |
Why?
|
| Virus Replication | 2 | 2008 | 709 | 0.130 |
Why?
|
| Cetuximab | 2 | 2020 | 472 | 0.130 |
Why?
|
| Choledochal Cyst | 1 | 1994 | 13 | 0.130 |
Why?
|
| Physicians | 1 | 2023 | 882 | 0.130 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2020 | 600 | 0.130 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2022 | 962 | 0.130 |
Why?
|
| Cholecystitis | 1 | 1994 | 52 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2020 | 1146 | 0.130 |
Why?
|
| In Situ Nick-End Labeling | 3 | 2007 | 448 | 0.130 |
Why?
|
| Blood Transfusion | 2 | 2007 | 583 | 0.130 |
Why?
|
| Surgical Mesh | 1 | 2016 | 209 | 0.130 |
Why?
|
| Biliary Tract Diseases | 1 | 1994 | 61 | 0.120 |
Why?
|
| Artificial Intelligence | 1 | 2018 | 388 | 0.120 |
Why?
|
| Quinolines | 1 | 2017 | 383 | 0.120 |
Why?
|
| Carbonic Anhydrases | 1 | 2014 | 44 | 0.120 |
Why?
|
| bcl-2-Associated X Protein | 7 | 2006 | 367 | 0.120 |
Why?
|
| Sex Factors | 6 | 2020 | 2139 | 0.120 |
Why?
|
| Pregnancy Outcome | 2 | 1994 | 643 | 0.120 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2010 | 665 | 0.120 |
Why?
|
| Anticoagulants | 1 | 2019 | 787 | 0.120 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2017 | 444 | 0.120 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2010 | 2232 | 0.120 |
Why?
|
| Unnecessary Procedures | 1 | 2014 | 104 | 0.120 |
Why?
|
| Continuity of Patient Care | 1 | 2016 | 225 | 0.120 |
Why?
|
| Heart Neoplasms | 2 | 2009 | 214 | 0.120 |
Why?
|
| Glucose | 2 | 2021 | 1248 | 0.120 |
Why?
|
| Fibrosarcoma | 4 | 2008 | 135 | 0.120 |
Why?
|
| Age Factors | 6 | 2020 | 5377 | 0.120 |
Why?
|
| Pyrimidines | 3 | 2017 | 3518 | 0.120 |
Why?
|
| Cost-Benefit Analysis | 2 | 2015 | 945 | 0.110 |
Why?
|
| Stents | 1 | 2020 | 1096 | 0.110 |
Why?
|
| Macrophages, Alveolar | 1 | 1993 | 67 | 0.110 |
Why?
|
| Tobacco Use | 1 | 2013 | 54 | 0.110 |
Why?
|
| DNA Primers | 2 | 2013 | 1399 | 0.110 |
Why?
|
| Feasibility Studies | 6 | 2021 | 2292 | 0.110 |
Why?
|
| Brain Neoplasms | 4 | 2020 | 4849 | 0.110 |
Why?
|
| Myoblasts | 1 | 2013 | 72 | 0.110 |
Why?
|
| Bayes Theorem | 2 | 2018 | 1021 | 0.110 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 1085 | 0.110 |
Why?
|
| DNA, Neoplasm | 2 | 2017 | 1910 | 0.110 |
Why?
|
| Prodrugs | 1 | 2014 | 217 | 0.110 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2013 | 161 | 0.110 |
Why?
|
| Acute Kidney Injury | 1 | 2020 | 739 | 0.110 |
Why?
|
| Receptor, ErbB-2 | 2 | 2017 | 2518 | 0.110 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2013 | 160 | 0.110 |
Why?
|
| Hernia, Diaphragmatic | 1 | 2013 | 121 | 0.110 |
Why?
|
| Cation Transport Proteins | 1 | 2014 | 199 | 0.110 |
Why?
|
| Diagnostic Imaging | 3 | 2011 | 1162 | 0.110 |
Why?
|
| Quality Improvement | 1 | 2019 | 851 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2017 | 4938 | 0.110 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2000 | 675 | 0.110 |
Why?
|
| Internship and Residency | 1 | 2023 | 1375 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 651 | 0.110 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2015 | 413 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 715 | 0.100 |
Why?
|
| Microscopy, Fluorescence | 2 | 2013 | 769 | 0.100 |
Why?
|
| Neoplasms, Second Primary | 4 | 2006 | 1350 | 0.100 |
Why?
|
| Neoplasm Proteins | 3 | 2020 | 3230 | 0.100 |
Why?
|
| Chromosome Aberrations | 3 | 2016 | 1960 | 0.100 |
Why?
|
| Semantics | 2 | 2008 | 58 | 0.100 |
Why?
|
| Receptor, EphA2 | 1 | 2013 | 132 | 0.100 |
Why?
|
| Pyrazoles | 2 | 2014 | 1471 | 0.100 |
Why?
|
| Omentum | 1 | 2012 | 96 | 0.100 |
Why?
|
| Immunoenzyme Techniques | 5 | 2015 | 1165 | 0.100 |
Why?
|
| Thyroid Neoplasms | 1 | 2022 | 1866 | 0.100 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2022 | 2341 | 0.100 |
Why?
|
| Bronchi | 2 | 2010 | 326 | 0.100 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 573 | 0.100 |
Why?
|
| Pneumonia | 3 | 2013 | 751 | 0.100 |
Why?
|
| Disease Models, Animal | 3 | 2020 | 7222 | 0.100 |
Why?
|
| MCF-7 Cells | 1 | 2013 | 550 | 0.100 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2018 | 1283 | 0.100 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2021 | 1763 | 0.100 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 1048 | 0.100 |
Why?
|
| Thromboembolism | 2 | 2012 | 155 | 0.100 |
Why?
|
| MAP Kinase Signaling System | 1 | 2015 | 848 | 0.100 |
Why?
|
| Clinical Trials as Topic | 6 | 2018 | 3719 | 0.100 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2015 | 661 | 0.100 |
Why?
|
| Cell Differentiation | 4 | 2017 | 4078 | 0.100 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2012 | 173 | 0.100 |
Why?
|
| Mice, Knockout | 3 | 2019 | 5710 | 0.100 |
Why?
|
| DNA Methylation | 2 | 2020 | 2669 | 0.100 |
Why?
|
| False Positive Reactions | 2 | 2014 | 355 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2010 | 2508 | 0.100 |
Why?
|
| Cytokines | 4 | 2020 | 2809 | 0.100 |
Why?
|
| Case-Control Studies | 7 | 2016 | 6100 | 0.100 |
Why?
|
| Surveys and Questionnaires | 3 | 2023 | 5687 | 0.090 |
Why?
|
| Neoplasms, Experimental | 3 | 2007 | 750 | 0.090 |
Why?
|
| Drug Therapy | 1 | 2011 | 205 | 0.090 |
Why?
|
| Linear Models | 3 | 2018 | 1085 | 0.090 |
Why?
|
| Surgical Procedures, Operative | 1 | 2013 | 383 | 0.090 |
Why?
|
| Mediastinoscopy | 1 | 2009 | 31 | 0.090 |
Why?
|
| Etoposide | 4 | 2019 | 870 | 0.090 |
Why?
|
| Cost of Illness | 2 | 2023 | 498 | 0.090 |
Why?
|
| Laminin | 1 | 2010 | 194 | 0.090 |
Why?
|
| DNA Fragmentation | 4 | 2005 | 198 | 0.090 |
Why?
|
| Protein Biosynthesis | 1 | 2013 | 889 | 0.090 |
Why?
|
| Reproducibility of Results | 4 | 2021 | 6009 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2018 | 4549 | 0.090 |
Why?
|
| RNA, Small Interfering | 3 | 2013 | 2216 | 0.090 |
Why?
|
| Body Mass Index | 3 | 2013 | 2203 | 0.090 |
Why?
|
| Proteoglycans | 1 | 2010 | 259 | 0.090 |
Why?
|
| Cancer Vaccines | 2 | 2007 | 697 | 0.090 |
Why?
|
| Thiazoles | 1 | 2013 | 726 | 0.090 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 1678 | 0.090 |
Why?
|
| Positron Emission Tomography Computed Tomography | 3 | 2021 | 833 | 0.080 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2016 | 1021 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 1 | 2011 | 482 | 0.080 |
Why?
|
| International Cooperation | 1 | 2010 | 323 | 0.080 |
Why?
|
| Biopsy, Needle | 4 | 2007 | 1363 | 0.080 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2013 | 489 | 0.080 |
Why?
|
| Radiation Dosage | 1 | 2013 | 1014 | 0.080 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2010 | 447 | 0.080 |
Why?
|
| Lymphocyte Activation | 4 | 2020 | 1688 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 2 | 2013 | 3203 | 0.080 |
Why?
|
| Retinoblastoma Protein | 1 | 2010 | 335 | 0.080 |
Why?
|
| Neurosurgical Procedures | 1 | 2013 | 609 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase 9 | 1 | 2008 | 33 | 0.080 |
Why?
|
| Telephone | 2 | 2021 | 163 | 0.080 |
Why?
|
| DNA Mutational Analysis | 4 | 2020 | 2283 | 0.080 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2013 | 519 | 0.080 |
Why?
|
| HeLa Cells | 2 | 2008 | 1643 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2008 | 135 | 0.080 |
Why?
|
| Drug Combinations | 1 | 2010 | 621 | 0.080 |
Why?
|
| Plasmids | 2 | 2007 | 837 | 0.080 |
Why?
|
| Overweight | 1 | 2011 | 484 | 0.080 |
Why?
|
| Genotype | 4 | 2020 | 4109 | 0.080 |
Why?
|
| Densitometry | 1 | 2007 | 45 | 0.080 |
Why?
|
| Coxsackie and Adenovirus Receptor-Like Membrane Protein | 1 | 2007 | 38 | 0.080 |
Why?
|
| Probability | 5 | 2010 | 866 | 0.080 |
Why?
|
| Clinical Protocols | 3 | 2015 | 467 | 0.080 |
Why?
|
| Sepsis | 1 | 2013 | 652 | 0.080 |
Why?
|
| Information Storage and Retrieval | 1 | 2008 | 135 | 0.080 |
Why?
|
| Aprotinin | 1 | 2007 | 34 | 0.080 |
Why?
|
| Image Enhancement | 1 | 2011 | 561 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2009 | 327 | 0.080 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2010 | 328 | 0.080 |
Why?
|
| Immunologic Memory | 2 | 2020 | 374 | 0.080 |
Why?
|
| Premedication | 2 | 2005 | 135 | 0.080 |
Why?
|
| Adenofibroma | 1 | 2007 | 20 | 0.080 |
Why?
|
| Cell Adhesion | 1 | 2010 | 1008 | 0.070 |
Why?
|
| Cell Cycle | 6 | 2013 | 2084 | 0.070 |
Why?
|
| Regression Analysis | 4 | 2013 | 1546 | 0.070 |
Why?
|
| Loss of Heterozygosity | 1 | 2009 | 602 | 0.070 |
Why?
|
| Histones | 2 | 2017 | 1466 | 0.070 |
Why?
|
| Receptors, Virus | 1 | 2007 | 157 | 0.070 |
Why?
|
| Internet | 2 | 2008 | 706 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2008 | 311 | 0.070 |
Why?
|
| Radiation, Ionizing | 1 | 2007 | 187 | 0.070 |
Why?
|
| Hemostatics | 1 | 2007 | 88 | 0.070 |
Why?
|
| Genetic Variation | 1 | 2015 | 2086 | 0.070 |
Why?
|
| B-Lymphocytes | 3 | 2020 | 1294 | 0.070 |
Why?
|
| Hemostasis | 1 | 2007 | 109 | 0.070 |
Why?
|
| Pneumonia, Aspiration | 1 | 2006 | 41 | 0.070 |
Why?
|
| Gastroesophageal Reflux | 2 | 2010 | 334 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 6 | 2014 | 2314 | 0.070 |
Why?
|
| Collagen | 1 | 2010 | 752 | 0.070 |
Why?
|
| Mediastinal Neoplasms | 1 | 2010 | 423 | 0.070 |
Why?
|
| Mice, Inbred NOD | 2 | 2019 | 905 | 0.070 |
Why?
|
| Annexin A1 | 1 | 2006 | 39 | 0.070 |
Why?
|
| Leiomyoma | 1 | 2007 | 145 | 0.070 |
Why?
|
| MicroRNAs | 2 | 2011 | 2947 | 0.070 |
Why?
|
| Radiography | 4 | 2013 | 1904 | 0.070 |
Why?
|
| Neoplasm Grading | 3 | 2017 | 1742 | 0.070 |
Why?
|
| Capecitabine | 2 | 2019 | 388 | 0.070 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2017 | 235 | 0.070 |
Why?
|
| Operative Time | 2 | 2019 | 217 | 0.070 |
Why?
|
| Gene Deletion | 3 | 2009 | 1442 | 0.070 |
Why?
|
| Cardiovascular Diseases | 3 | 2015 | 2195 | 0.070 |
Why?
|
| Research | 1 | 2008 | 415 | 0.070 |
Why?
|
| Incidental Findings | 1 | 2007 | 272 | 0.070 |
Why?
|
| Amifostine | 1 | 2006 | 97 | 0.070 |
Why?
|
| Deoxycytidine | 3 | 2019 | 1353 | 0.070 |
Why?
|
| Chemoprevention | 2 | 2013 | 241 | 0.070 |
Why?
|
| Tetracyclines | 1 | 2005 | 17 | 0.070 |
Why?
|
| Thymidylate Synthase | 1 | 2005 | 53 | 0.070 |
Why?
|
| Oncolytic Viruses | 1 | 2008 | 204 | 0.070 |
Why?
|
| Paraffin Embedding | 2 | 2018 | 226 | 0.070 |
Why?
|
| Medical Informatics | 1 | 2008 | 198 | 0.070 |
Why?
|
| Antirheumatic Agents | 2 | 2018 | 167 | 0.070 |
Why?
|
| Benzimidazoles | 1 | 2008 | 428 | 0.070 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2005 | 17 | 0.070 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 2005 | 24 | 0.070 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2008 | 650 | 0.070 |
Why?
|
| STAT3 Transcription Factor | 1 | 2012 | 1121 | 0.060 |
Why?
|
| Academic Medical Centers | 2 | 2019 | 672 | 0.060 |
Why?
|
| Observer Variation | 1 | 2007 | 671 | 0.060 |
Why?
|
| Decision Trees | 3 | 2006 | 178 | 0.060 |
Why?
|
| Culture Media, Conditioned | 1 | 2005 | 260 | 0.060 |
Why?
|
| Life Tables | 1 | 2004 | 120 | 0.060 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2005 | 177 | 0.060 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2005 | 129 | 0.060 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2007 | 297 | 0.060 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2005 | 87 | 0.060 |
Why?
|
| Metaplasia | 2 | 2021 | 383 | 0.060 |
Why?
|
| Immunization | 2 | 2007 | 397 | 0.060 |
Why?
|
| Breast Neoplasms | 7 | 2010 | 15694 | 0.060 |
Why?
|
| ROC Curve | 3 | 2013 | 1183 | 0.060 |
Why?
|
| Mediastinum | 2 | 2019 | 268 | 0.060 |
Why?
|
| 3' Untranslated Regions | 1 | 2005 | 343 | 0.060 |
Why?
|
| Thymectomy | 2 | 2020 | 79 | 0.060 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 1265 | 0.060 |
Why?
|
| Epidemiologic Methods | 2 | 2017 | 254 | 0.060 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2009 | 2326 | 0.060 |
Why?
|
| Molecular Targeted Therapy | 3 | 2020 | 2330 | 0.060 |
Why?
|
| Leiomyosarcoma | 1 | 2005 | 223 | 0.060 |
Why?
|
| Genomic Instability | 1 | 2007 | 519 | 0.060 |
Why?
|
| DNA Repair | 1 | 2012 | 1872 | 0.060 |
Why?
|
| Drainage | 3 | 2021 | 416 | 0.060 |
Why?
|
| Abdomen | 1 | 2005 | 332 | 0.060 |
Why?
|
| Chromosome Deletion | 1 | 2008 | 1005 | 0.060 |
Why?
|
| Research Design | 1 | 2011 | 1544 | 0.060 |
Why?
|
| Morbidity | 2 | 2015 | 397 | 0.060 |
Why?
|
| Flavoproteins | 1 | 2003 | 33 | 0.060 |
Why?
|
| Obesity | 2 | 2013 | 2884 | 0.060 |
Why?
|
| Liver | 2 | 2010 | 2961 | 0.060 |
Why?
|
| Staurosporine | 1 | 2003 | 143 | 0.060 |
Why?
|
| Cell Line | 3 | 2006 | 5114 | 0.060 |
Why?
|
| Maryland | 1 | 2022 | 48 | 0.060 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2015 | 566 | 0.050 |
Why?
|
| Bias | 1 | 2023 | 205 | 0.050 |
Why?
|
| 2-Aminopurine | 1 | 2002 | 9 | 0.050 |
Why?
|
| Immunoglobulin M | 1 | 2023 | 347 | 0.050 |
Why?
|
| Thrombectomy | 1 | 2003 | 158 | 0.050 |
Why?
|
| Income | 1 | 2023 | 222 | 0.050 |
Why?
|
| Immunophenotyping | 2 | 2017 | 1681 | 0.050 |
Why?
|
| Cyclosporine | 1 | 2003 | 278 | 0.050 |
Why?
|
| Smoking | 3 | 2021 | 2440 | 0.050 |
Why?
|
| Vena Cava, Inferior | 1 | 2003 | 190 | 0.050 |
Why?
|
| Karnofsky Performance Status | 2 | 2012 | 175 | 0.050 |
Why?
|
| Enzyme Induction | 1 | 2002 | 249 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2011 | 3251 | 0.050 |
Why?
|
| Time-to-Treatment | 2 | 2015 | 292 | 0.050 |
Why?
|
| Models, Biological | 2 | 2008 | 3254 | 0.050 |
Why?
|
| Matched-Pair Analysis | 1 | 2021 | 103 | 0.050 |
Why?
|
| Membrane Potentials | 1 | 2003 | 424 | 0.050 |
Why?
|
| Plasma Cells | 1 | 2022 | 192 | 0.050 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2002 | 101 | 0.050 |
Why?
|
| Prescriptions | 1 | 2021 | 65 | 0.050 |
Why?
|
| Ecosystem | 1 | 2022 | 111 | 0.050 |
Why?
|
| Proteomics | 2 | 2023 | 1380 | 0.050 |
Why?
|
| Lymphoma | 1 | 2010 | 1467 | 0.050 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2005 | 436 | 0.050 |
Why?
|
| Confidence Intervals | 2 | 2018 | 756 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2008 | 806 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 2 | 2016 | 1290 | 0.050 |
Why?
|
| Four-Dimensional Computed Tomography | 2 | 2014 | 226 | 0.050 |
Why?
|
| Acute Disease | 3 | 1994 | 2422 | 0.050 |
Why?
|
| Injections, Intralesional | 3 | 2012 | 164 | 0.050 |
Why?
|
| Minority Groups | 1 | 2023 | 322 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 1 | 2008 | 1491 | 0.050 |
Why?
|
| Cause of Death | 2 | 2015 | 752 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2007 | 1335 | 0.050 |
Why?
|
| Intercostal Nerves | 1 | 2020 | 33 | 0.050 |
Why?
|
| Liver Neoplasms | 2 | 2011 | 4557 | 0.050 |
Why?
|
| Gene Knockdown Techniques | 2 | 2017 | 1077 | 0.050 |
Why?
|
| Benchmarking | 1 | 2023 | 273 | 0.050 |
Why?
|
| Sex Distribution | 2 | 2016 | 495 | 0.050 |
Why?
|
| Drug Therapy, Combination | 3 | 2017 | 2315 | 0.050 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2002 | 503 | 0.050 |
Why?
|
| Interferons | 1 | 2002 | 291 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 2 | 2019 | 2483 | 0.050 |
Why?
|
| Miniaturization | 1 | 2020 | 47 | 0.050 |
Why?
|
| Neck | 1 | 2022 | 383 | 0.050 |
Why?
|
| Neuroendocrine Tumors | 1 | 2006 | 634 | 0.050 |
Why?
|
| Vinblastine | 1 | 2001 | 453 | 0.050 |
Why?
|
| Exome | 2 | 2017 | 1239 | 0.050 |
Why?
|
| Patient Care Management | 1 | 2020 | 94 | 0.050 |
Why?
|
| Aftercare | 1 | 2021 | 259 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2003 | 1313 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2023 | 1021 | 0.040 |
Why?
|
| Reference Values | 2 | 2018 | 1099 | 0.040 |
Why?
|
| Gamma Rays | 1 | 2020 | 242 | 0.040 |
Why?
|
| Thyroidectomy | 1 | 2022 | 486 | 0.040 |
Why?
|
| Epithelial Cells | 2 | 2021 | 1818 | 0.040 |
Why?
|
| Pemetrexed | 1 | 2019 | 102 | 0.040 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2002 | 422 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2015 | 1217 | 0.040 |
Why?
|
| Pain Measurement | 2 | 2020 | 953 | 0.040 |
Why?
|
| Anesthetics, Local | 1 | 2020 | 163 | 0.040 |
Why?
|
| Cell Division | 3 | 2005 | 2489 | 0.040 |
Why?
|
| Self Report | 1 | 2023 | 756 | 0.040 |
Why?
|
| Cell Cycle Proteins | 4 | 2004 | 2045 | 0.040 |
Why?
|
| Forecasting | 1 | 2002 | 694 | 0.040 |
Why?
|
| Bronchoscopy | 2 | 2000 | 474 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2002 | 604 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 2021 | 289 | 0.040 |
Why?
|
| Quinazolines | 2 | 2014 | 923 | 0.040 |
Why?
|
| Antigens, CD20 | 1 | 2019 | 206 | 0.040 |
Why?
|
| Comorbidity | 3 | 2013 | 2352 | 0.040 |
Why?
|
| Constriction, Pathologic | 1 | 2020 | 310 | 0.040 |
Why?
|
| Nerve Block | 1 | 2020 | 176 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 2023 | 764 | 0.040 |
Why?
|
| Adenosine | 1 | 2020 | 289 | 0.040 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2017 | 182 | 0.040 |
Why?
|
| Triage | 1 | 2020 | 252 | 0.040 |
Why?
|
| Clone Cells | 1 | 2020 | 555 | 0.040 |
Why?
|
| Quebec | 1 | 2018 | 20 | 0.040 |
Why?
|
| Protons | 2 | 2012 | 473 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2020 | 486 | 0.040 |
Why?
|
| Clonal Evolution | 1 | 2020 | 253 | 0.040 |
Why?
|
| Protein Binding | 1 | 2005 | 3438 | 0.040 |
Why?
|
| Carcinoma, Small Cell | 1 | 2001 | 408 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2003 | 2063 | 0.040 |
Why?
|
| Adenine | 2 | 2014 | 631 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2003 | 1945 | 0.040 |
Why?
|
| Costs and Cost Analysis | 2 | 2010 | 306 | 0.040 |
Why?
|
| Medicare | 2 | 2015 | 860 | 0.040 |
Why?
|
| North America | 1 | 2018 | 314 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2023 | 1819 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2019 | 557 | 0.040 |
Why?
|
| Spine | 1 | 1999 | 293 | 0.040 |
Why?
|
| Palliative Care | 3 | 2020 | 2037 | 0.040 |
Why?
|
| Acid Anhydride Hydrolases | 1 | 2017 | 84 | 0.040 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2009 | 1237 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2023 | 1016 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2023 | 598 | 0.040 |
Why?
|
| E2F Transcription Factors | 3 | 2003 | 132 | 0.040 |
Why?
|
| Glycolysis | 1 | 2020 | 519 | 0.040 |
Why?
|
| Hydrazones | 1 | 2017 | 42 | 0.040 |
Why?
|
| Prosthesis Design | 1 | 2020 | 749 | 0.040 |
Why?
|
| Plasma Substitutes | 1 | 1996 | 11 | 0.040 |
Why?
|
| Los Angeles | 1 | 1996 | 31 | 0.040 |
Why?
|
| Kidney Neoplasms | 2 | 2009 | 3022 | 0.040 |
Why?
|
| Thrombosis | 1 | 2003 | 781 | 0.040 |
Why?
|
| CD57 Antigens | 1 | 2016 | 20 | 0.040 |
Why?
|
| DNA, Viral | 1 | 1999 | 694 | 0.040 |
Why?
|
| Benzazepines | 1 | 2017 | 108 | 0.040 |
Why?
|
| Isotonic Solutions | 1 | 1996 | 46 | 0.040 |
Why?
|
| Interleukin-7 | 1 | 1997 | 95 | 0.040 |
Why?
|
| Mice, Inbred C3H | 3 | 2007 | 385 | 0.040 |
Why?
|
| Atrial Fibrillation | 1 | 2004 | 719 | 0.040 |
Why?
|
| Eligibility Determination | 1 | 2016 | 77 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2020 | 470 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2005 | 1823 | 0.030 |
Why?
|
| Thioredoxin Reductase 1 | 1 | 2016 | 15 | 0.030 |
Why?
|
| HLA-A2 Antigen | 1 | 2017 | 159 | 0.030 |
Why?
|
| A549 Cells | 1 | 2016 | 124 | 0.030 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2016 | 134 | 0.030 |
Why?
|
| Blood Volume | 1 | 1996 | 100 | 0.030 |
Why?
|
| Transfusion Reaction | 1 | 1996 | 102 | 0.030 |
Why?
|
| Platelet Transfusion | 1 | 1996 | 156 | 0.030 |
Why?
|
| Dimensional Measurement Accuracy | 1 | 2015 | 14 | 0.030 |
Why?
|
| Serum Albumin | 1 | 1996 | 257 | 0.030 |
Why?
|
| Child | 5 | 2018 | 29154 | 0.030 |
Why?
|
| Perioperative Period | 1 | 2016 | 155 | 0.030 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2017 | 355 | 0.030 |
Why?
|
| Telemetry | 1 | 2015 | 39 | 0.030 |
Why?
|
| Methylation | 1 | 2017 | 597 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2018 | 974 | 0.030 |
Why?
|
| Genome-Wide Association Study | 2 | 2017 | 2265 | 0.030 |
Why?
|
| Aminopyridines | 1 | 2017 | 212 | 0.030 |
Why?
|
| Plasma | 1 | 1996 | 158 | 0.030 |
Why?
|
| Mastectomy, Segmental | 1 | 2021 | 1026 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 4744 | 0.030 |
Why?
|
| Lactates | 1 | 2015 | 112 | 0.030 |
Why?
|
| Adenosine Monophosphate | 1 | 2015 | 76 | 0.030 |
Why?
|
| Oxygenases | 1 | 2014 | 26 | 0.030 |
Why?
|
| Rats | 2 | 2003 | 6086 | 0.030 |
Why?
|
| Age Distribution | 1 | 2016 | 698 | 0.030 |
Why?
|
| Abdominal Abscess | 1 | 1994 | 26 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 524 | 0.030 |
Why?
|
| Prevalence | 2 | 2016 | 3260 | 0.030 |
Why?
|
| Severity of Illness Index | 3 | 2015 | 4320 | 0.030 |
Why?
|
| Gene Editing | 1 | 2017 | 216 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 527 | 0.030 |
Why?
|
| Cell Separation | 3 | 2005 | 612 | 0.030 |
Why?
|
| Colonic Neoplasms | 1 | 2003 | 1390 | 0.030 |
Why?
|
| Stromal Cells | 1 | 2018 | 825 | 0.030 |
Why?
|
| Hedgehog Proteins | 1 | 2017 | 424 | 0.030 |
Why?
|
| bcl-X Protein | 2 | 2008 | 196 | 0.030 |
Why?
|
| Heart | 2 | 2012 | 1223 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2017 | 1163 | 0.030 |
Why?
|
| Drug Stability | 1 | 2014 | 105 | 0.030 |
Why?
|
| Amino Acid Sequence | 2 | 2017 | 4233 | 0.030 |
Why?
|
| Carbonic Anhydrase IX | 1 | 2014 | 36 | 0.030 |
Why?
|
| Erythrocyte Transfusion | 1 | 1996 | 212 | 0.030 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2002 | 1248 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2018 | 703 | 0.030 |
Why?
|
| Fetal Death | 1 | 1994 | 113 | 0.030 |
Why?
|
| Threonine | 1 | 2014 | 161 | 0.030 |
Why?
|
| Genes, Reporter | 3 | 2006 | 798 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2017 | 323 | 0.030 |
Why?
|
| Day Care, Medical | 1 | 2013 | 15 | 0.030 |
Why?
|
| Methionine | 1 | 2014 | 159 | 0.030 |
Why?
|
| Benzodioxoles | 1 | 2013 | 29 | 0.030 |
Why?
|
| Cholecystectomy | 1 | 1994 | 107 | 0.030 |
Why?
|
| Appendectomy | 1 | 1994 | 124 | 0.030 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2009 | 852 | 0.030 |
Why?
|
| Deglutition Disorders | 2 | 2008 | 447 | 0.030 |
Why?
|
| Medical Audit | 1 | 1994 | 188 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2017 | 582 | 0.030 |
Why?
|
| Homeostasis | 1 | 2018 | 950 | 0.030 |
Why?
|
| Informed Consent | 1 | 2016 | 419 | 0.030 |
Why?
|
| Protein Array Analysis | 1 | 2016 | 501 | 0.030 |
Why?
|
| Molecular Structure | 1 | 2014 | 515 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2013 | 289 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2014 | 324 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2019 | 1863 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 2015 | 571 | 0.030 |
Why?
|
| Injections, Intravenous | 2 | 2006 | 573 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 1303 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2019 | 1026 | 0.030 |
Why?
|
| Enteral Nutrition | 1 | 1995 | 316 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2014 | 875 | 0.030 |
Why?
|
| DNA Damage | 1 | 2001 | 1954 | 0.030 |
Why?
|
| Manometry | 1 | 2012 | 74 | 0.030 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 1993 | 118 | 0.030 |
Why?
|
| Chills | 1 | 2012 | 16 | 0.030 |
Why?
|
| Decision Making | 1 | 2020 | 1287 | 0.030 |
Why?
|
| Bacterial Infections | 1 | 1996 | 479 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2014 | 931 | 0.030 |
Why?
|
| Gastroscopy | 1 | 2012 | 134 | 0.030 |
Why?
|
| Pressure | 1 | 2012 | 215 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2018 | 973 | 0.030 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2013 | 245 | 0.030 |
Why?
|
| Gastrointestinal Motility | 1 | 2012 | 92 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2013 | 245 | 0.030 |
Why?
|
| Alcoholism | 1 | 1994 | 285 | 0.030 |
Why?
|
| Pregnancy | 2 | 1994 | 7573 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2012 | 660 | 0.020 |
Why?
|
| Quality of Life | 2 | 2023 | 4532 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 2006 | 3976 | 0.020 |
Why?
|
| Dumping Syndrome | 1 | 2010 | 7 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2016 | 1385 | 0.020 |
Why?
|
| Pandemics | 1 | 2020 | 1559 | 0.020 |
Why?
|
| STAT5 Transcription Factor | 1 | 2012 | 214 | 0.020 |
Why?
|
| Standard of Care | 1 | 2012 | 243 | 0.020 |
Why?
|
| Esophagitis | 1 | 2012 | 202 | 0.020 |
Why?
|
| Peptides | 1 | 2017 | 1479 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2012 | 700 | 0.020 |
Why?
|
| Infusions, Intravenous | 2 | 2006 | 1382 | 0.020 |
Why?
|
| Carcinoid Tumor | 1 | 2013 | 280 | 0.020 |
Why?
|
| Macrophages | 1 | 2017 | 1304 | 0.020 |
Why?
|
| Elective Surgical Procedures | 1 | 2012 | 250 | 0.020 |
Why?
|
| Forced Expiratory Volume | 1 | 2012 | 314 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2018 | 929 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2015 | 925 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2008 | 1299 | 0.020 |
Why?
|
| Tertiary Care Centers | 1 | 2012 | 403 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2015 | 717 | 0.020 |
Why?
|
| Vomiting | 1 | 2012 | 354 | 0.020 |
Why?
|
| Cell Nucleolus | 1 | 2010 | 89 | 0.020 |
Why?
|
| Watchful Waiting | 1 | 2012 | 289 | 0.020 |
Why?
|
| Osteopontin | 1 | 2010 | 148 | 0.020 |
Why?
|
| Pilot Projects | 2 | 2011 | 2803 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2010 | 209 | 0.020 |
Why?
|
| Cell Communication | 1 | 1993 | 509 | 0.020 |
Why?
|
| Phenotype | 1 | 2021 | 6295 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 2011 | 682 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2012 | 717 | 0.020 |
Why?
|
| Relative Biological Effectiveness | 1 | 2011 | 219 | 0.020 |
Why?
|
| Nausea | 1 | 2012 | 525 | 0.020 |
Why?
|
| Adenoviruses, Human | 2 | 2000 | 181 | 0.020 |
Why?
|
| Calgranulin B | 1 | 2009 | 22 | 0.020 |
Why?
|
| Cornified Envelope Proline-Rich Proteins | 1 | 2009 | 30 | 0.020 |
Why?
|
| Interleukin-4 | 1 | 1990 | 284 | 0.020 |
Why?
|
| Methylmethacrylate | 2 | 1999 | 15 | 0.020 |
Why?
|
| Caspases, Initiator | 1 | 2009 | 16 | 0.020 |
Why?
|
| Keratin-5 | 1 | 2009 | 57 | 0.020 |
Why?
|
| Health Care Costs | 1 | 1994 | 674 | 0.020 |
Why?
|
| Mitotic Index | 1 | 2009 | 162 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 1997 | 2022 | 0.020 |
Why?
|
| Algorithms | 2 | 2014 | 3890 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 2005 | 2927 | 0.020 |
Why?
|
| Fever | 1 | 2012 | 497 | 0.020 |
Why?
|
| Respiratory Tract Diseases | 1 | 2009 | 111 | 0.020 |
Why?
|
| Bone Cements | 2 | 1999 | 45 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2017 | 3154 | 0.020 |
Why?
|
| Europe | 1 | 2010 | 649 | 0.020 |
Why?
|
| Risk | 1 | 2013 | 1972 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2011 | 666 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2011 | 1037 | 0.020 |
Why?
|
| Database Management Systems | 1 | 2008 | 63 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2008 | 48 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2013 | 589 | 0.020 |
Why?
|
| Systems Integration | 1 | 2008 | 76 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2012 | 483 | 0.020 |
Why?
|
| Eukaryotic Initiation Factors | 1 | 2008 | 65 | 0.020 |
Why?
|
| Respiration | 1 | 2011 | 447 | 0.020 |
Why?
|
| Gene Expression Regulation | 3 | 2008 | 4053 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2009 | 356 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2010 | 1053 | 0.020 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2001 | 363 | 0.020 |
Why?
|
| Desmin | 1 | 2007 | 63 | 0.020 |
Why?
|
| Intraoperative Complications | 1 | 2010 | 301 | 0.020 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2009 | 301 | 0.020 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2010 | 500 | 0.020 |
Why?
|
| Lac Operon | 1 | 2007 | 122 | 0.020 |
Why?
|
| Movement | 1 | 2011 | 556 | 0.020 |
Why?
|
| Surgical Stapling | 1 | 2007 | 36 | 0.020 |
Why?
|
| Bone Neoplasms | 2 | 2011 | 2576 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 1988 | 295 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 1993 | 5637 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2008 | 298 | 0.020 |
Why?
|
| Mycobacterium bovis | 1 | 2007 | 67 | 0.020 |
Why?
|
| Heart Diseases | 1 | 2013 | 732 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2012 | 987 | 0.020 |
Why?
|
| Esophageal Stenosis | 1 | 2007 | 83 | 0.020 |
Why?
|
| Spinal Cord | 1 | 2010 | 690 | 0.020 |
Why?
|
| Synaptophysin | 1 | 2006 | 79 | 0.020 |
Why?
|
| Chromogranin A | 1 | 2006 | 65 | 0.020 |
Why?
|
| Chromogranins | 1 | 2006 | 84 | 0.020 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2006 | 62 | 0.020 |
Why?
|
| User-Computer Interface | 1 | 2008 | 286 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 1991 | 1144 | 0.020 |
Why?
|
| Pathology | 1 | 2007 | 101 | 0.020 |
Why?
|
| Genes, MDR | 1 | 2006 | 38 | 0.020 |
Why?
|
| Pain, Intractable | 2 | 1998 | 171 | 0.020 |
Why?
|
| Guanine | 1 | 2007 | 151 | 0.020 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2006 | 142 | 0.020 |
Why?
|
| Drug Costs | 1 | 2007 | 144 | 0.020 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2006 | 102 | 0.020 |
Why?
|
| Monocytes | 1 | 1990 | 788 | 0.020 |
Why?
|
| Antigens, CD34 | 1 | 2007 | 593 | 0.020 |
Why?
|
| Jejunostomy | 1 | 2006 | 52 | 0.020 |
Why?
|
| Biological Therapy | 1 | 2006 | 58 | 0.020 |
Why?
|
| Genes, bcl-2 | 1 | 2006 | 166 | 0.020 |
Why?
|
| Lymphocytes | 1 | 1991 | 1234 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2006 | 259 | 0.020 |
Why?
|
| Fatigue | 1 | 2012 | 1239 | 0.020 |
Why?
|
| CDC2 Protein Kinase | 1 | 2006 | 176 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 2006 | 246 | 0.020 |
Why?
|
| Information Dissemination | 1 | 2008 | 272 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2013 | 1258 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2007 | 479 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 1990 | 1038 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2009 | 492 | 0.020 |
Why?
|
| Receptors, Leukotriene B4 | 1 | 2005 | 7 | 0.020 |
Why?
|
| Fatty Alcohols | 1 | 2005 | 10 | 0.020 |
Why?
|
| Glycols | 1 | 2005 | 8 | 0.020 |
Why?
|
| Leukotriene B4 | 1 | 2005 | 20 | 0.020 |
Why?
|
| Critical Pathways | 1 | 2006 | 149 | 0.020 |
Why?
|
| I-kappa B Kinase | 1 | 2006 | 250 | 0.020 |
Why?
|
| Celecoxib | 1 | 2005 | 200 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2006 | 280 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2006 | 334 | 0.020 |
Why?
|
| Suture Techniques | 1 | 2007 | 319 | 0.020 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 215 | 0.020 |
Why?
|
| Interferon-alpha | 1 | 2009 | 889 | 0.020 |
Why?
|
| Down-Regulation | 1 | 1990 | 2074 | 0.020 |
Why?
|
| Actins | 1 | 2007 | 608 | 0.020 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2005 | 200 | 0.020 |
Why?
|
| Caspase 12 | 1 | 2004 | 5 | 0.020 |
Why?
|
| Arachidonate 15-Lipoxygenase | 1 | 2005 | 90 | 0.020 |
Why?
|
| Thoracoscopy | 1 | 2005 | 101 | 0.020 |
Why?
|
| Tunicamycin | 1 | 2004 | 20 | 0.020 |
Why?
|
| Brefeldin A | 1 | 2004 | 22 | 0.020 |
Why?
|
| Caspase 7 | 1 | 2004 | 35 | 0.020 |
Why?
|
| Oncolytic Virotherapy | 1 | 2007 | 280 | 0.020 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2005 | 169 | 0.020 |
Why?
|
| Nephrectomy | 1 | 2009 | 779 | 0.020 |
Why?
|
| Protein Phosphatase 1 | 1 | 2004 | 79 | 0.010 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2005 | 324 | 0.010 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2011 | 882 | 0.010 |
Why?
|
| Protein Phosphatase 2 | 1 | 2004 | 88 | 0.010 |
Why?
|
| Drug Carriers | 1 | 2005 | 327 | 0.010 |
Why?
|
| Global Health | 1 | 2009 | 657 | 0.010 |
Why?
|
| Awards and Prizes | 1 | 2005 | 98 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 2005 | 297 | 0.010 |
Why?
|
| Apoptosis Inducing Factor | 1 | 2003 | 19 | 0.010 |
Why?
|
| Physician's Role | 1 | 2005 | 238 | 0.010 |
Why?
|
| Isotretinoin | 1 | 2003 | 158 | 0.010 |
Why?
|
| Breast | 1 | 2010 | 1344 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2005 | 483 | 0.010 |
Why?
|
| Liposomes | 1 | 2005 | 684 | 0.010 |
Why?
|
| Antigens, Differentiation | 1 | 2004 | 238 | 0.010 |
Why?
|
| Infant | 1 | 2018 | 13310 | 0.010 |
Why?
|
| Tumor Protein p73 | 1 | 2002 | 105 | 0.010 |
Why?
|
| Molecular Chaperones | 1 | 2004 | 264 | 0.010 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2004 | 214 | 0.010 |
Why?
|
| Heat-Shock Proteins | 1 | 2004 | 311 | 0.010 |
Why?
|
| Mastectomy, Radical | 1 | 2002 | 39 | 0.010 |
Why?
|
| Antibodies, Viral | 2 | 2000 | 1320 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2003 | 445 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2012 | 4314 | 0.010 |
Why?
|
| Ion Transport | 1 | 2002 | 79 | 0.010 |
Why?
|
| Cytoskeletal Proteins | 1 | 2004 | 492 | 0.010 |
Why?
|
| Heart Arrest, Induced | 1 | 2002 | 87 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2018 | 16273 | 0.010 |
Why?
|
| Luciferases | 1 | 2003 | 445 | 0.010 |
Why?
|
| Trastuzumab | 1 | 2004 | 696 | 0.010 |
Why?
|
| Renal Insufficiency | 1 | 2005 | 321 | 0.010 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2002 | 209 | 0.010 |
Why?
|
| Lamins | 1 | 2001 | 9 | 0.010 |
Why?
|
| Lamin Type B | 1 | 2001 | 9 | 0.010 |
Why?
|
| Caspase 6 | 1 | 2001 | 15 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 1997 | 4638 | 0.010 |
Why?
|
| Vascular Neoplasms | 1 | 2002 | 114 | 0.010 |
Why?
|
| Software | 1 | 2008 | 1321 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 2001 | 418 | 0.010 |
Why?
|
| Nuclear Proteins | 2 | 2002 | 3343 | 0.010 |
Why?
|
| beta Catenin | 1 | 2004 | 688 | 0.010 |
Why?
|
| DNA, Recombinant | 1 | 2000 | 121 | 0.010 |
Why?
|
| Thoracostomy | 1 | 2000 | 43 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2001 | 471 | 0.010 |
Why?
|
| Orthopedic Fixation Devices | 1 | 1999 | 20 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2004 | 1113 | 0.010 |
Why?
|
| Laminectomy | 1 | 1999 | 52 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 2017 | 5061 | 0.010 |
Why?
|
| Methylmethacrylates | 1 | 1998 | 16 | 0.010 |
Why?
|
| Antibody Formation | 1 | 2000 | 383 | 0.010 |
Why?
|
| Safety | 1 | 2000 | 465 | 0.010 |
Why?
|
| Bone Plates | 1 | 1998 | 47 | 0.010 |
Why?
|
| Kyphosis | 1 | 1998 | 43 | 0.010 |
Why?
|
| Back Pain | 1 | 1998 | 61 | 0.010 |
Why?
|
| Pulmonary Atelectasis | 1 | 1998 | 46 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 2000 | 429 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2000 | 699 | 0.010 |
Why?
|
| Pulmonary Artery | 1 | 2002 | 499 | 0.010 |
Why?
|
| Bone Screws | 1 | 1998 | 84 | 0.010 |
Why?
|
| Methods | 1 | 1997 | 189 | 0.010 |
Why?
|
| Retinoblastoma-Binding Protein 1 | 1 | 1997 | 54 | 0.010 |
Why?
|
| Transcription Factor DP1 | 1 | 1997 | 57 | 0.010 |
Why?
|
| Orthopedic Procedures | 1 | 1999 | 146 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 2000 | 419 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2004 | 1555 | 0.010 |
Why?
|
| Genes, Retinoblastoma | 1 | 1997 | 86 | 0.010 |
Why?
|
| Muscle Weakness | 1 | 1998 | 116 | 0.010 |
Why?
|
| Cervical Vertebrae | 1 | 1998 | 205 | 0.010 |
Why?
|
| Lumbar Vertebrae | 1 | 1998 | 245 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2008 | 6942 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2004 | 3001 | 0.010 |
Why?
|
| Histological Techniques | 1 | 1997 | 65 | 0.010 |
Why?
|
| Catheters, Indwelling | 1 | 2000 | 374 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2005 | 830 | 0.010 |
Why?
|
| Thorax | 1 | 1997 | 213 | 0.010 |
Why?
|
| Walking | 1 | 1998 | 277 | 0.010 |
Why?
|
| Proteins | 1 | 2004 | 1963 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2000 | 554 | 0.010 |
Why?
|
| Pulmonary Embolism | 1 | 1998 | 329 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2002 | 1823 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2000 | 1271 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 1990 | 4654 | 0.010 |
Why?
|
| Enhancer Elements, Genetic | 1 | 1996 | 467 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2000 | 6089 | 0.010 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 1996 | 494 | 0.010 |
Why?
|
| Pain | 1 | 1999 | 1658 | 0.010 |
Why?
|
| Concanavalin A | 1 | 1990 | 67 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 1996 | 3101 | 0.010 |
Why?
|
| Antigens, Ly | 1 | 1988 | 49 | 0.000 |
Why?
|
| Thy-1 Antigens | 1 | 1988 | 51 | 0.000 |
Why?
|
| Rats, Inbred Strains | 1 | 1988 | 410 | 0.000 |
Why?
|
| Lipopolysaccharides | 1 | 1990 | 558 | 0.000 |
Why?
|
| Antibody Specificity | 1 | 1988 | 334 | 0.000 |
Why?
|
| Melphalan | 1 | 1990 | 834 | 0.000 |
Why?
|
| Mice, Inbred Strains | 1 | 1988 | 521 | 0.000 |
Why?
|
| Thymus Gland | 1 | 1988 | 294 | 0.000 |
Why?
|
| Spleen | 1 | 1988 | 676 | 0.000 |
Why?
|